[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615033":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":55,"collaborators":24,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":24,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":24,"enrollmentInfo":66,"targetDuration":24,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":41,"whyStopped":24,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Up-front individualized dosing algorithm","EXPERIMENTAL","Clinical decision support to encourage use of an individualized cefepime dosing algorithm based on eGFRcr-cysC and weight.",[13],"Other: Up-front individualized dosing algorithm",{"label":15,"type":16,"description":17,"interventionNames":18},"Usual Care","ACTIVE_COMPARATOR","The standard of care group will receive empiric dosing of cefepime, using an institutional antimicrobial guide based on four categories of eGFRcr.",[19],"Other: Usual Care",[21,25],{"type":6,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"An individualized cefepime dosing algorithm will be used to determine the cefepime dose and interval. The dose recommendation will be provided using the EHR-prompts to the clinical care team and ordered and\u002For verified by the ICU pharmacist using an established collaborative practice agreement. As a pragmatic trial, at any point care teams may modify the empiric or subsequent dose based on their clinical judgement.",[9],null,{"type":6,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"The standard of care group will receive empiric dosing guided by an institutional antimicrobial guide. Cefepime is typically dosed at 0.5-2 g every 8-24 h according to categorical thresholds of estimated creatinine clearance (eGFRcr). Cystatin C and eGFRcr-cys can be calculated and used at clinicians' discretion to aid in drug dose determination.",[15],[29],{"name":30,"affiliation":5,"role":31},"Erin Barreto, PharmD, PhD","PRINCIPAL_INVESTIGATOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},"Gerald W. Flaby Jr., LRT, RRT","CONTACT","507-422-3462","flaby.gerald@mayo.edu",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Mayo Clinic in Rochester","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":48,"coordinates":49},"Point",[50,51],-92.4699,44.02163,{"lat":51,"lon":50},[54],{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},{"type":31,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Erin Barreto","Principal Investigator","100615033","bloom-pragmatic-feasibility-trial-100615033",false,"NCT07287332","BLOOM: Pragmatic Feasibility Trial","Inclusion Criteria:\n\n* Adults ≥18 years of age\n* Admitted to one of the ICUs at the study center\n* Prescribed cefepime therapy by the care team\n\nExclusion Criteria:\n\n* Individuals will be those with a cephalosporin allergy\n* Received \\>1 dose of cefepime in the 24 hours before ICU admission\n* Transferred from an external hospital without compatible EHR\n* Does not have a cystatin C and a creatinine available for drug dosing\n* Acute kidney injury stage 2 or higher\n* Receiving renal replacement therapy\n* Treated with extracorporeal membrane oxygenation\n* Undergoing molecular adsorbent recirculating therapy at the time of beta-lactam initiation\n* Pregnant\n* Incarcerated\n* Declined Minnesota research authorization","ALL","18 Years",{"count":67,"type":68},300,"ESTIMATED","INTERVENTIONAL",[71],"NA","The goal of this study is to compare two different ways of dosing cefepime, an antibiotic for very sick patients - the usual approach to dosing or a new dosing method. The new dosing method uses only doses that are available in normal care, but choosing between the different doses is based on more information about the patient's body including their kidney function. The primary purpose of this study is to test how easy it is for healthcare professionals to use the new dosing method and how best to conduct the trial. The study will also assess if the new dosing method helps patients recover faster and reduces side effects.",[74,75],"Sepsis","Infection",[77,74,78,79,80,81,82],"Beta-lactam antibiotics","Septic shock","Pharmacokinetics","Personalized medicine","Therapeutic drug monitoring","Infectious disease","2026-02-04",{"date":85,"type":86},"2026-02-06","ACTUAL",{"date":88,"type":86},"2026-01-15",{"date":90,"type":68},"2027-07",{"name":5,"class":6},1]